Eton Pharmaceuticals/ETON

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.

Ticker

ETON

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sean Brynjelsen

Employees

30

Headquarters

Deer park, United States

ETON Metrics

BasicAdvanced
$91M
Market cap
104.94
P/E ratio
$0.03
EPS
1.27
Beta
-
Dividend rate
$91M
1.27035
$5.81
$2.42
66K
1.586
1.434
32.4
3.34%
6.83%
5.72%
104.936
2.659
5.886
10.016
28.21
40.71%
113.51%
832.68%

What the Analysts think about ETON

Analyst Ratings

Majority rating from 1 analysts.
Buy

ETON Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-10.12% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.9M
8.22%
Net income
-$800K
-63.64%
Profit margin
-10.12%
-66.41%

ETON Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 57.14%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.18
-$0.02
-$0.09
-$0.03
-
Expected
-$0.09
-$0.10
-$0.04
-$0.07
-$0.07
Surprise
-300.00%
-80.00%
125.00%
-57.14%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Eton Pharmaceuticals stock?

Eton Pharmaceuticals (ETON) has a market cap of $91M as of June 15, 2024.

What is the P/E ratio for Eton Pharmaceuticals stock?

The price to earnings (P/E) ratio for Eton Pharmaceuticals (ETON) stock is 104.94 as of June 15, 2024.

Does Eton Pharmaceuticals stock pay dividends?

No, Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Eton Pharmaceuticals dividend payment date?

Eton Pharmaceuticals (ETON) stock does not pay dividends to its shareholders.

What is the beta indicator for Eton Pharmaceuticals?

Eton Pharmaceuticals (ETON) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Eton Pharmaceuticals stock price target?

The target price for Eton Pharmaceuticals (ETON) stock is $8, which is NaN% below the current price of $. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Eton Pharmaceuticals stock

Buy or sell Eton Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing